ViBo Health Europe participates in the ESA Business Incubation Centre Portugal.
The European Space Agency (ESA) sponsors the BIC program.
For more information, read our press release about this great application of space technology.
We have been accepted into the prestigious incubator of the Instituto Pedro Nunes (IPN) in Coimbra, Portugal.
The IPN Incubadora has been recognized as one world's top incubators.
ViBo Health USA has now been accepted into the UCLA Magnify Incubator.
UCLA has been ranked #1 out of 225 universities in creating start-ups.
A substantial proportion of poor health is preventable. From heart disease to diabetes, hundreds of millions of people worldwide are suffering from preventable conditions.
The consequence for individuals is loss of independence, years of disability, or death. The cost to society is enormous. US healthcare spending attributable to modifiable risk factors is $730 billion per year or 27% of total healthcare spending.
Early diagnosis is crucial to help delay or prevent the onset of preventable disease. However, the tools we have for early screening are ineffective, cumbersome, and inaccessible.
We will offer many of the benefits of traditional laboratory tests without the pain of a blood draw and the waiting times associated with wet laboratory tests. We are disrupting the conventional disease detection model of blood and laboratory testing, which is expensive, time-consuming, often performed late, and only accessible in clinical settings.
Diabetes is one of the most pervasive and expensive diseases in the world. In the last 20 years, the number of adults diagnosed with diabetes in the US has more than doubled .1 in 10 American adults is now diagnosed with diabetes.
.png)
Staggeringly, 1 in 3 Americans have pre-diabetes, yet the vast majority (80%) don’t know they have it.
.png)
The cost of allowing pre-diabetes to go undetected and develop into Type 2 diabetes, is enormous. In the US, $1 in every $4 spent on healthcare is for diabetes care. Employers pay $8,000 per year for a diabetic employee. Preventing diabetes provides a company with an ROI over 10 years of $55,000 per employee.
.png)
Blood tests are the only reliable test for pre-diabetes. They are typically performed too late following the appearance of symptoms, requiring specialist personnel, and performed only by healthcare providers.
.png)
There is therefore an urgent need to make pre-diabetes detection quick, easy, and accessible to help prevent or delay the onset of diabetes.
.png)
DigiScan™ transforms early detection of pre-diabetes and disrupts the current diagnosis model which misses 80% of cases.
.png)
Our DigiScan™ product is under development and has multiple benefits for pre-diabetes detection:
Accurately detects multiple biomarkers (metabolites) validated for the identification of pre-diabetes, including glucose variability, insulin, A1C, lipid changes, lactate, and CRP.
Accessible: Available in easy-to-access locations such as gyms, pharmacies, and workplaces.
Easy to use: No need for specialist personnel, instant results, and instant recommendations.
Quick: 10-second finger scan.
Inexpensive: No direct cost to the end user.
Small footprint: Size of a breadbox.
The ViBo Health team are experienced medical device, business, and finance entrepreneurs with a proven track record. Dr. Gil Travish (CEO & Founder) has over 20 years of experience in hard med-tech, and physics, and has founded four companies including two in medical devices. Ron Stone (CFO) is a serial entrepreneur and former CFO and COO of Ronco Corporation. Dr. Katariina Salonen (Clinical Lead) is an Emergency Room Doctor with training in Surgery and work experience internationally (Finland, US, and Brazil). Peter John (Director of Finance) was previously CFO of two successful startups and is an experienced financial modeler with a master’s degree in economics from Oxford University and a PwC-trained financial analyst.
ViBo Health Inc.
℅ Terasaki Institute for Biomedical Research
11570 W. Olympic Blvd.
Office 138
Los Angeles CA 90064
USA
ViBo Health (Europe)
℅ IPN-Incubadora
Rua Pedro Nunes
3030 - 199 Coimbra
Portugal
Our tests can be used several times per week to offer a timeline (longitudinal) and predict healthcare status changes on an individual, and population bases. The tests provide data for the individual user to maintain and control a health status.
GPs, clinicians, and health workers can be provided diagnostic indicators of disease. The privacy of the customers is secured throughout, and all services are opt-in.
The customer benefits through cost savings for tests and the comfort of knowing “how they are doing” and what to expect at the next doctor visit. Clinicians benefit from longitudinal, dynamic and comparable data for each customer that is currently difficult or not practical to obtain.
The healthcare system and the entire society benefits from better informed public health efforts, cost savings, more actionable data, and improved outcomes.
